Safety of Intracameral Moxifloxacin and Dexamethasone in Phacoemulsification: 3-Year Results

Monday, April 20, 2015: 3:16 PM
Room 1B (San Diego Convention Center)
Fernando Aguilera-Zarate, MD

Determine safety of a combination of moxifloxacine + dexametazone used intracemeraly in phacoemulsification.

Two groups are included. inclusion criteria: no other ocular or systemic pathology but cataract. complete preop and postop evaluations included specular microscopy, biomicroscopy and macular OCT. In 24 eyes intracameral moxifloxacion + dexametazone was used and 24 using BSS at the end of phaco. Patients were seen postop days 1, 7, 30-43, and 3, 6, 12, 24, 36 months. Comparison of clinical findings between the 2 groups were analyzed.

Twenty-eight patients completed the 3 year deadline. Ocular inflammation (hogan classification) was less at 1 day postop, and were the same at the 7th day. There were not statistical differences after one week postop in specular microscopy, biomicroscopy,\and macular OCT.

The combination of intracameral moxifloxacin+dexametazone in phacoemulsification  is safe for  ocular structures.